Novo Nordisk's Pill Launch Faces a Jury of Divided Analysts
Published on 08/10/2026 at 13:11 | Redaktion boerse-global.de
The countdown to September 1, 2026 has begun in earnest at Novo Nordisk's Copenhagen headquarters. That is the date the Danish drugmaker brings its oral Wegovy tablet to Germany, and waiting lists for the pill-based alternative to the weekly injection are already filling up. For a stock down 8.28 percent so far this year, the launch represents either a turning point or another chapter in a story of unmet expectations.
Wall Street cannot seem to agree which one it will be. The divergence played out in real time this week as Citi trimmed its price target to 310 Danish kroner from 330, while BMO Capital moved the other way, lifting its target to $47 from $45. Bank of America, Deutsche Bank, Goldman Sachs and Barclays all held steady with neutral ratings during the first week of August. The spread captures a market wrestling with conflicting signals: a raised outlook on one hand, a clinical setback with financial consequences on the other.
The Pill's Promise and the Production Question
Novo Nordisk's strategic pivot is unambiguous. The company that built its empire on injectable weight-loss drugs now wants oral semaglutide to drive the next growth phase, having already tested the formula in the US market. The German rollout will serve as a litmus test for whether the group can replicate its dominant stateside position — roughly 89 percent market share of oral obesity prescriptions — on an international stage.
Success hinges on two forces pulling in opposite directions. Can Novo Nordisk scale up tablet production quickly enough to avoid the supply bottlenecks that once hampered the injectable version? And how aggressively will Eli Lilly press its advantage with next-generation compounds? The two questions are intertwined: any production delay hands momentum directly to the rival that is already closing the gap.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The bull case rests on tangible evidence. The stock trades 33.49 percent above its 52-week low of €30.25, suggesting the sell-off has already priced in a considerable amount of bad news. The oral Wegovy version has generated more than 5 million prescriptions in the US since its launch six months ago, a signal of strong adoption among both patients and physicians. The CagriSema candidate met its primary endpoint in the REDEFINE-9 study, with an FDA decision expected by the end of 2026 and a potential market entry in early 2027.
Management has also raised its 2026 guidance, supported by quarterly revenue of 78.5 billion Danish kroner. Geographic expansion continues apace: Ozempic launched in India on December 12, 2025, tapping into the world's second-largest population of Type-2 diabetics. If the German tablet rollout proceeds as smoothly as the American one and production holds steady, the stock could find support near its 200-day average of €40.30 — almost exactly where it currently trades.
The Bearish Counterweight
The other side of the ledger carries considerable weight. Eli Lilly posted a 48 percent year-over-year revenue jump in the second quarter, and its successor candidate Retatrutide demonstrated weight loss of up to 28.3 percent in Phase 3 trials — a figure that could pressure Novo Nordisk's existing portfolio. The company's own pipeline suffered a blow when the ZEUS study of Ziltivekimab missed its primary endpoint, a failure that will trigger an impairment charge in the third quarter.
Analyst caution is palpable. Bernstein maintains its "Underperform" rating, while DZ Bank sticks with "Hold" despite a modestly raised price target. The stock sits 26.39 percent below its 52-week high of €54.86, and technical pressure remains elevated. Analysts repeatedly flag the same concern: the tablet's success depends entirely on production capacity, historically the company's weak spot.
Buybacks and the Road Ahead
The analyst debate has not deterred Novo Nordisk from its share repurchase program. Through August 3, the company had bought back 27,064,179 B-shares at an average price of 278.35 Danish kroner since February 4, representing a transaction value of roughly 7.53 billion kroner. The group now holds 44,249,480 of its own B-shares, about one percent of share capital. The program forms part of a twelve-month buyback of up to 15 billion kroner that began on February 4, 2026; the current tranche, running from May 6, 2026 to February 1, 2027, covers up to 11.2 billion kroner. A company that continues buying its own stock despite lowered sales forecasts and billion-kroner write-downs signals at least some confidence in its valuation.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The stock rose 2.69 percent to €40.99 on Friday, and has gained 6.6 percent since the half-year results were published, even after an initial US trading dip in response to acknowledged weakness in the American business. The ZEUS failure announcement came a day earlier, and the shares have been up 2.7 percent since.
Two dates now dominate the calendar. The dividend payment arrives on August 25, 2026, following the ex-dividend date of August 17. The FDA decision on CagriSema is expected toward the end of the year. Between them sits the German tablet launch — the moment when Novo Nordisk must prove it can translate American oral-market dominance into European success. Whether the stock can close its 26.39 percent gap to the yearly high may well depend on how smoothly the pills move off production lines and into pharmacies this September.
Ad
Novo Nordisk Stock: New Analysis - 10 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
